PMV Pharmaceuticals Inc Ordinary Shares PMVP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PMVP is a good fit for your portfolio.
News
-
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
-
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
-
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
-
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
Trading Information
- Previous Close Price
- $1.81
- Day Range
- $1.69–1.80
- 52-Week Range
- $1.18–9.72
- Bid/Ask
- $1.70 / $1.79
- Market Cap
- $86.94 Mil
- Volume/Avg
- 204,183 / 589,645
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 63
- Website
- https://www.pmvpharma.com
Comparables
Valuation
Metric
|
PMVP
|
ORIC
|
CRNX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.39 | 1.98 | 5.59 |
Price/Sales | — | — | 639.90 |
Price/Cash Flow | — | — | — |
Price/Earnings
PMVP
ORIC
CRNX
Financial Strength
Metric
|
PMVP
|
ORIC
|
CRNX
|
---|---|---|---|
Quick Ratio | 14.47 | 10.18 | 12.92 |
Current Ratio | 14.78 | 10.39 | 13.07 |
Interest Coverage | — | — | — |
Quick Ratio
PMVP
ORIC
CRNX
Profitability
Metric
|
PMVP
|
ORIC
|
CRNX
|
---|---|---|---|
Return on Assets (Normalized) | −23.12% | −33.07% | −38.81% |
Return on Equity (Normalized) | −25.57% | −36.66% | −44.79% |
Return on Invested Capital (Normalized) | −27.79% | −36.24% | −45.62% |
Return on Assets
PMVP
ORIC
CRNX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cwvkgngchd | Qdvk | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xfgxdqkz | Fzwlv | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pdvnrqzx | Dqrhwgx | $99.5 Bil | |
MRNA
| Moderna Inc | Qmngknt | Wfcr | $38.8 Bil | |
ARGX
| argenx SE ADR | Xgwjfsq | Zzpj | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Pghyntk | Xtsj | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lcqgnvvj | Mjxzhb | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bkvnkzz | Ddpxw | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kckrnpqks | Jwxdcyp | $12.5 Bil | |
INCY
| Incyte Corp | Lqzqjbf | Tzgpcd | $11.6 Bil |